

CLAIMS

1. A compound of formula **(I)**



(I)








wherein

R1 is ;

R2 is selected from hydrogen, F, Cl, Br, OSO_2C_{1-3}alkyl, or C_{1-3}alkyl;

R3 is selected from hydrogen, F, Cl, Br, CN, CF_3, SO_2C_{1-3}alkyl, $CONH_2$ or $SO_2N\mathbf{R^4R^5}$, wherein **R4** and **R5** together with the nitrogen atom to which they are attached form a azetidine, pyrrolidine or piperidine ring; or

R1 is selected from

, , , , ,  or ;

X is selected from O, S or CF_2;

Y is selected from O or S;


Q is selected from CH or N;

R6 is selected from C_{1-3}alkyl, wherein said C_{1-3}alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC_{1-3}alkyl, $N(C_{1-3}alkyl)_2$, cyclopropyl, or tetrapydropyran;

R7 is selected from hydrogen, F, Cl or CH_3;

or a pharmaceutically-acceptable salt thereof for use in therapy.

2. The compound according to claim 1, wherein

R1 is 

;

or a pharmaceutically acceptable salt thereof.

3. The compound according to either claim 1 or claim 2, wherein

X is O;

R6 is C_{1-3}alkyl; and

R7 is hydrogen;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 selected from:

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,7-dimethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

4'-[(2*S*)-2-Cyano-2-{[(2*S*)-1,4-oxazepan-2-ylcarbonyl]amino}ethyl]biphenyl-3-yl methanesulfonate;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-1,2-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(trifluoromethyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(3',4'-difluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzothiazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-7-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4-{3-[2-(dimethylamino)ethyl]-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl}phenyl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1*H*-indol-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(7-fluoro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(propan-2-yl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(5-cyanothiophen-2-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-2-(4'-Carbamoyl-3'-fluorobiphenyl-4-yl)-1-cyanoethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(tetrahydro-2*H*-pyran-4-ylmethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4-(7-Chloro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4'-(Azetidin-1-ylsulfonyl)biphenyl-4-yl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-fluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;


(2*S*)-*N*-{(1*S*)-2-[4-(1,3-Benzothiazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide; or

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-1,2,3,4-tetrahydroquinoxalin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

and pharmaceutically acceptable salts thereof.


5. The compound according to claim 1 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide



;

or a pharmaceutically acceptable salt thereof.


6. The compound according to claim 1 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide



.


.

7. A compound of formula **(I)**



(I)

wherein




R1 is ;





R2 is selected from hydrogen, F, Cl, Br, OSO_2C_{1-3}alkyl, or C_{1-3}alkyl;

R3 is selected from hydrogen, F, Cl, Br, CN, CF_3, SO_2C_{1-3}alkyl, $CONH_2$ or SO_2N**R4R5**,

wherein **R4** and **R5** together with the nitrogen atom to which they are attached form a azetidine, pyrrolidine or piperidine ring; or

R1 is selected from

, , ,

, ,  or ;

X is selected from O, S or CF_2;

Y is selected from O or S;


Q is selected from CH or N;

R6 is selected from C_{1-3}alkyl, wherein said C_{1-3}alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC_{1-3}alkyl, $N(C_{1-3}alkyl)_2$, cyclopropyl, or tetrapydropyran;

R7 is selected from hydrogen, F, Cl or CH_3;

or a pharmaceutically-acceptable salt thereof for use in treating asthma or chronic obstructive pulmonary disease.

8. The compound according to claim 7, wherein

R1 is ;

or a pharmaceutically acceptable salt thereof.

9. The compound according to either claim 7 or claim 8, wherein

X is O;

R6 is C_{1-3}alkyl; and

R7 is hydrogen;

or a pharmaceutically acceptable salt thereof.

10. The compound of the formula **(I)** according to claim 7 selected from:

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,7-dimethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

4'-[(2*S*)-2-Cyano-2-{[(2*S*)-1,4-oxazepan-2-ylcarbonyl]amino}ethyl]biphenyl-3-yl methanesulfonate;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-1,2-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(trifluoromethyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(3',4'-difluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzothiazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-7-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4-{3-[2-(dimethylamino)ethyl]-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl}phenyl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1*H*-indol-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(7-fluoro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(propan-2-yl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(5-cyanothiophen-2-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-2-(4'-Carbamoyl-3'-fluorobiphenyl-4-yl)-1-cyanoethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(tetrahydro-2*H*-pyran-4-ylmethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4-(7-Chloro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4'-(Azetidin-1-ylsulfonyl)biphenyl-4-yl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-fluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;


(2*S*)-*N*-{(1*S*)-2-[4-(1,3-Benzothiazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide; or

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-1,2,3,4-tetrahydroquinoxalin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

and pharmaceutically acceptable salts thereof.


11. The compound according to claim 7 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide



;


or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 7 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide




.

13. Use of a compound of formula **(I)**



(I)

wherein




R1 is ;





R2 is selected from hydrogen, F, Cl, Br, OSO_2C_{1-3}alkyl, or C_{1-3}alkyl;

R3 is selected from hydrogen, F, Cl, Br, CN, CF_3, SO_2C_{1-3}alkyl, $CONH_2$ or SO_2N**R4R5**,

wherein **R4** and **R5** together with the nitrogen atom to which they are attached form a azetidine, pyrrolidine or piperidine ring; or

R1 is selected from

, , ,

, ,  or ;

X is selected from O, S or CF_2;

Y is selected from O or S;


Q is selected from CH or N;

R6 is selected from C_{1-3}alkyl, wherein said C_{1-3}alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC_{1-3}alkyl, $N(C_{1-3}alkyl)_2$, cyclopropyl, or tetrapydropyran;

R7 is selected from hydrogen, F, Cl or CH_3;

or a pharmaceutically-acceptable salt in the manufacture of a medicament for use in treating asthma or chronic obstructive pulmonary disease.

14. The use of the compound according to claim 13, wherein

R1 is 

;

or a pharmaceutically acceptable salt thereof.

15. The use of the compound according to either claim 13 or claim 14, wherein

X is O;

R6 is C_{1-3}alkyl; and

R7 is hydrogen;

or a pharmaceutically acceptable salt thereof.

16. The use of the compound of the formula **(I)** according to claim 13 selected from:

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,7-dimethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

4'-[(2*S*)-2-Cyano-2-{[(2*S*)-1,4-oxazepan-2-ylcarbonyl]amino}ethyl]biphenyl-3-yl methanesulfonate;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-1,2-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(trifluoromethyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(3',4'-difluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzothiazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-7-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4-{3-[2-(dimethylamino)ethyl]-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl}phenyl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1*H*-indol-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(7-fluoro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(propan-2-yl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(5-cyanothiophen-2-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-2-(4'-Carbamoyl-3'-fluorobiphenyl-4-yl)-1-cyanoethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(tetrahydro-2*H*-pyran-4-ylmethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4-(7-Chloro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4'-(Azetidin-1-ylsulfonyl)biphenyl-4-yl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-fluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;


(2*S*)-*N*-{(1*S*)-2-[4-(1,3-Benzothiazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide; or

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-1,2,3,4-tetrahydroquinoxalin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

and pharmaceutically acceptable salts thereof.


17. The use of the compound according to claim 13 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide



;


or a pharmaceutically acceptable salt thereof.

18. The use of the compound according to claim 13 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide




.

19. A combination of the compound of formula **(I)**



(I)




wherein





R1 is  ;

R2 is selected from hydrogen, F, Cl, Br, OSO_2C_{1-3}alkyl, or C_{1-3}alkyl;

R3 is selected from hydrogen, F, Cl, Br, CN, CF_3, SO_2C_{1-3}alkyl, $CONH_2$ or $SO_2N\mathbf{R^4R^5}$, wherein **R4** and **R5** together with the nitrogen atom to which they are attached form a azetidine, pyrrolidine or piperidine ring; or

R1 is selected from

 ,  ,  ,

 ,  ,  or  ;

X is selected from O, S or CF_2;

Y is selected from O or S;

Q is selected from CH or N;

R6 is selected from C_{1-3}alkyl, wherein said C_{1-3}alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC_{1-3}alkyl, $N(C_{1-3}alkyl)_2$, cyclopropyl, or tetrapydropyran;


R7 is selected from hydrogen, F, Cl or CH_3;

or a pharmaceutically-acceptable salt thereof, and one or more agents independently selected from:

- a non-steroidal glucocorticoid receptor agonist;
- a selective β_2 adrenoceptor agonist;
- a phosphodiesterase inhibitor;
- a protease inhibitor;
- a glucocorticoid;
- an anticholinergic agent;
- a modulator of chemokine receptor function; and

an inhibitor of kinase function.

20. The combination according to claim 19, wherein

R1 is 

;

or a pharmaceutically acceptable salt thereof

21. The combination according to either claim 19 or claim 20, wherein

X is O;

R6 is C_{1-3}alkyl; and

R7 is hydrogen;

or a pharmaceutically acceptable salt thereof

22. The combination according to claim 19 selected from:

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,7-dimethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

4'-[(2*S*)-2-Cyano-2-{[(2*S*)-1,4-oxazepan-2-ylcarbonyl]amino}ethyl]biphenyl-3-yl methanesulfonate;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-1,2-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(trifluoromethyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(3',4'-difluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzothiazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-7-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4-{3-[2-(dimethylamino)ethyl]-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl}phenyl)ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1*H*-indol-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(7-fluoro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(propan-2-yl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(5-cyanothiophen-2-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-2-(4'-Carbamoyl-3'-fluorobiphenyl-4-yl)-1-cyanoethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(tetrahydro-2*H*-pyran-4-ylmethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4-(7-Chloro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-{4-[2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-{(1*S*)-2-[4'-(Azetidin-1-ylsulfonyl)biphenyl-4-yl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-fluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;


(2*S*)-*N*-{(1*S*)-2-[4-(1,3-Benzothiazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;

(2*S*)-*N*-[(1*S*)-1-Cyano-2-(4'-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide; or

(2*S*)-*N*-{(1*S*)-1-Cyano-2-[4-(4-methyl-3-oxo-1,2,3,4-tetrahydroquinoxalin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;

and pharmaceutically acceptable salts thereof.


23. The combination according to claim 19 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide



;

or a pharmaceutically acceptable salt thereof.

24. The combination according to claim 19 which is (2*S*)-*N*-{(1*S*)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide



.